John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses the design and objectives of the Phase Ib study assessing safety and preliminary efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Phase 1b Study in Patients with Large B-Cell Lymphoma
